Perspectives

April 15, 2022 2021 Annual Report: CEO Yvonne Greenstreet Reflects on an Important Year in the RNAi Revol ... In conjunction with the publishing of Alnylam's 2021 Annual Report, Alnylam's CEO Yvonne Greenstreet reflects on the year that was... Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
September 10, 2020 Brendan Martin on the Pharmaphorum Podcast Alnylam’s Brendan Martin, Head of Europe, Middle East, Africa, and Canada and General Manager for the UK & Ireland, recently spoke on the Pharmaphorum podcast. Read More ›
September 2, 2020 With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ... What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which... Read More ›
April 11, 2019 Letter to the Editor: Federal Research is Important, but Companies Turn it Into Actual Tre ... John Maraganore wrote a Letter to the Editor in The Washington Post about the importance of federal research... Read More ›
January 3, 2019 John Maraganore Talks RNAi on Chemical & Engineering News Podcast John Maraganore talks with Chemical & Engineering News' Lisa Jarvis and Ryan Cross on this episode of C&EN's Stereo Chemistry podcast. Read More ›
May 9, 2018 First Rounders: John Maraganore Our CEO John Maraganore, Ph.D. recently chatted with the Nature Biotechnology Podcast about his path into science, through research and ultimately into biotech. Read More ›